DNASE1L1

Importance

A fundamental common feature of all tumors is the disruption of apoptosis. Degenerated cells thus evade self-destruction, continue to grow and carry the risk of further degeneration through further mutations and increase in aggressiveness and malignancy.

DNaseX (DNase1L1) has a special feature that makes it suitable as a marker for the detection of cancer. The concentration of the DNaseX enzyme increases in tumor cells - in contrast to other DNases, whose concentration decreases in the course of tumor development.

DNaseX is generally produced in greater quantities in tumor cells in order to induce the desired programmed cell death. However, by synthesizing specific inhibitors, the tumor cell can suppress the enzyme activity of DNaseX and thus prevent the final apoptosis step, the DNA cutting.

The accumulation of DNaseX has been detected in all premalignant and malignant tumor types examined to date. The accumulation in cells occurs when DNaseX cannot fulfill its task. Then the cell continues to produce the DNaseX protein because it wants to induce apoptosis. This situation leads to higher and higher concentrations of DNaseX in the cell. If a DNaseX overproduction can be detected, this can be taken as an indicator of impaired apoptosis and as an indication of the development of tumors in the body.

The Apo10 epitope plays a special role in this process. This characteristic section of the protein sequence of the DNaseX enzyme can be identified diagnostically using the same-named monoclonal antibody Apo10 (DJ28D4).

The resulting accumulation of DNaseX (Apo10) in the nucleus also makes the detection easier - since the amount of Apo10 in the nucleus increases sharply.

Clinical application

DNaseX (Apo10) is already applied in diagnostic cancer screening. The enzymes DNaseX (Apo10) and TKTL1 are detected in PanTum Detect, a blood test used in combination with imaging techniques such as MRI and PET-CT for the early detection of cancer. The detection of DNaseX (Apo10) and TKTL1 in immune cells using EDIM technology provides clues to possible tumor disease. In case of an abnormal result, clarification by imaging techniques is recommended.

References

References

1. (September 1995). "A muscle-specific DNase I-like gene in human Xq28". Human Molecular Genetics.
2. (February 1996). "Cloning of a gene encoding a DNase I-like endonuclease in the human Xq28 region". Gene.
3. "DNASE1L1 deoxyribonuclease I-like 1". U.S. National Library of Medicine.
4. (April 1996). "Isolation, differential splicing and protein expression of a DNase on the human X chromosome". Cell Death and Differentiation.
5. "Protein mit dnase-aktivität".
6. (September 2005). "Trashing the genome: the role of nucleases during apoptosis". Nature Reviews. Molecular Cell Biology.
7. (August 2002). "Involvement of DNase gamma in apoptosis associated with myogenic differentiation of C2C12 cells". The Journal of Biological Chemistry.
8. (2008). "Altered deoxyribonuclease activity in cancer cells and its role in non toxic adjuvant cancer therapy with mixed vitamins C and K3". Anticancer Research.
9. (June 2003). "Changes in the topological expression of markers of differentiation and apoptosis in defined stages of human cervical dysplasia and carcinoma". Gynecologic Oncology.
10. (December 2013). "A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells". BMC Cancer.
11. (July 2022). "Epitope Detection in Monocytes (EDIM) As a New Method of Liquid Biopsy in Pediatric Rhabdomyosarcoma". Biomedicines.
12. (March 2016). "Analysis of circulating CD14+/CD16+ monocyte-derived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma". Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.
13. (October 2012). "O583 Apol0 - A New Biomarker for Early Detection of Disorders of Cell Proliferation and Solid Tumours". International Journal of Gynecology & Obstetrics.
14. (2020). "Biomarkers Apo10 and TKTL1: Epitope-detection in monocytes (EDIM) as a new diagnostic approach for cholangiocellular, pancreatic and colorectal carcinoma". Cancer Biomarkers.
15. (July 2007). "Apo-10'-lycopenoic acid inhibits lung cancer cell growth in vitro, and suppresses lung tumorigenesis in the A/J mouse model in vivo". Carcinogenesis.
16. (2022-05-20). "Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals". Journal of Clinical and Medical Images.
17. (October 2022). "Epitope detection in monocytes (EDIM) for liquid biopsy including identification of GD2 in childhood neuroblastoma-a pilot study". British Journal of Cancer.